Unlocking the Power of Enasidenib Tablets in Cancer Treatment

Enasidenib, also known by its brand name Idhifa, is a medication that specifically targets mutations in the isocitrate dehydrogenase 2 (IDH2) enzyme. This enzyme is found in about 12% of acute myeloid leukemia (AML) cases and is responsible for the uncontrolled growth of cancer cells. Enasidenib tablets works by inhibiting the mutated IDH2 enzyme, thus stopping the growth and proliferation of leukemia cells.This innovation marks a new era in healthcare, offering hope and advanced treatment options for patients worldwide. At Impomed Healthcare we are proud to be at the forefront of this medical breakthrough, empowering patients with the tools they need to reclaim their health and their lives.